Combined effects of oleoyl-estrone and a beta3-adrenergic agonist (CL316,243) on lipid stores of diet-induced overweight male Wistar rats.
Oleoyl-estrone (OE) decreases appetite, induces adipose tissue wasting and resets the ponderostat setting, sparing glucose and protein. The beta3-adrenergic agonists increase energy expenditure and lipolysis. We studied the combination of both treatments to enhance fat mobilization. Overweight male rats received oral OE for 10 days; they were compared with controls and rats receiving a beta3-adrenergic agonist, CL316,243 (B3A); another group received both OE and B3A. Serum 3-hydroxybutyrate, NEFA, triacylglycerols and glucose showed only slight changes in all groups vs. controls; OE-treated rats showed lower cholesterol. OE decreased food intake and B3A increased energy expenditure. OE rats lost about 15%, B3A 24%, and those receiving both compounds lost 39% of their initial total body energy. In all cases, most of this energy imbalance was accounted for by the loss of body lipid. The combined treatment of OE and B3A reduced food intake, nevertheless maintaining a high energy expenditure. The combination of a beta3-adrenergic agonist with OE may help compensate the short-lived effects of the agonist and enhance the lipid mobilization action of OE. The eventual combination of both compounds should be explored as a way to obtain faster and more effective ways to treat obesity.
Ferrer-Lorente
Raquel
R
Department of Nutrition and Food Science; Faculty of Biology, University of Barcelona, Av. Diagonal, 645, E-08028 Barcelona, Spain. rferrer@bio.ub.es
Cabot
Cristina
C
Fernández-López
José-Antonio
JA
Alemany
Marià
M
D020155:3-Hydroxybutyric Acid / Q000097:blood; D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000704:Analysis of Variance; D000818:Animals; D001786:Blood Glucose; D004149:Dioxoles / Q000494:pharmacology*; D004435:Eating / Q000187:drug effects; D004734:Energy Metabolism / Q000187:drug effects; D004970:Estrone / Q000031:analogs & derivatives* / Q000494:pharmacology; D005230:Fatty Acids, Nonesterified / Q000097:blood; D007333:Insulin Resistance / Q000502:physiology; D008053:Lipid Mobilization / Q000187:drug effects*; D008297:Male; D009765:Obesity / Q000378:metabolism*; D009829:Oleic Acids / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D014280:Triglycerides / Q000097:blood
D000318:Adrenergic beta-Agonists; D001786:Blood Glucose; D004149:Dioxoles; D005230:Fatty Acids, Nonesterified; D009829:Oleic Acids; D014280:Triglycerides; C076126:disodium (R,R)-5-(2-((2-(3-chlorophenyl)-2-hydroxyethyl)-amino)propyl)-1,3-benzodioxole-2,3-dicarboxylate; D004970:Estrone; C108709:oleoyl-estrone; D020155:3-Hydroxybutyric Acid